A Pain in the Bum

We see the look of dread on patients’ faces every single day. You come in with symptoms and we run the tests. Then comes the moment we have to break the news that it is indeed Gonorrhoea. The treatment is effective but it is not pleasant. For years the gold standard has been Ceftriaxone which requires an intramuscular injection. And yes it usually goes right in the buttock.

It is a literal pain in the bum that adds an extra layer of anxiety to an already stressful situation. Many of our patients ask if there is an alternative. For a long time the answer has been no because the bacteria that causes this infection is incredibly smart. It has learned to outsmart almost every pill we have thrown at it.

But that conversation is about to change.

The Superbug Crisis

We often talk about the looming threat of antibiotic resistance in our STD clinic. Neisseria gonorrhoeae is what we call a “superbug” in the making. Over the last century it has defeated penicillin and tetracyclines and fluoroquinolones. It eats them for breakfast.

We were getting dangerously close to a scenario where we had run out of options. Reports of super-Gonorrhoea have been popping up globally. It was a ticking time bomb. We needed a new weapon and it looks like science has finally delivered.

Enter Zoliflodacin

In December 2025 the medical world got the news we had been waiting for. The results of a massive Phase 3 trial called EAGLE-1 were published in The Lancet. They tested a brand new drug called Zoliflodacin.

This isn’t just a tweak of an old medicine. It is an entirely new class of antibiotic called a spiropyrimidinetrione. While older drugs try to stop the bacteria from replicating by attacking a specific part of its DNA machinery the bacteria had evolved to block those attacks. Zoliflodacin binds to a completely unique site on the enzyme. It is like changing the locks on a door that the burglar had already learned to pick.

The End of the Needle

The trial results were impressive. They compared a single oral dose of Zoliflodacin against the standard painful injection. The oral sachet was just as effective at curing infections in the urethra and cervix. It achieved a cure rate of over 96 percent.

This is a game changer for logistics and patient comfort. FDA approval followed swiftly under the brand name Nuzolvence. This marks the first new class of oral antibiotics for Gonorrhoea treatment we have seen in decades. It means we can treat patients quickly and painlessly without the need for needles or clinical procedures.

A Note of Caution

Now I have to be the sensible medical voice for a moment. This does not mean we should start popping these pills like sweets. The trial showed that while it works wonders for urogenital infections it was slightly less effective for infections in the throat. That is a common hiding spot for bacteria so testing the right sites is still crucial.

Public health authorities are also likely to treat this new drug as a reserve agent. We want to protect it so the bacteria doesn’t learn to resist this one too. It might be saved specifically for cases where the standard treatment fails or for people who cannot take cephalosporins. But having it in our arsenal is a massive relief.

Looking Ahead

This development echoes the hope we felt when reading about new treatments for resistant strains just a few years ago. It validates the push for “new chemistry” in medicine.

For you it means the future of STD testing and care is getting less invasive and more sophisticated. The fear of the needle shouldn’t stop you from getting checked.

Staying Safe in Singapore

While we wait for this new drug to become the standard on our shelves the current treatments are still highly effective if caught early. Don’t let fear or embarrassment delay your health check. Whether you are worried about symptoms or just want peace of mind we are here to sort it out quickly and confidentially.

Think you might have been exposed?
Book a confidential consultation with us today

References

• The Lancet Phase 3 Data: Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data. Available at: Innoviva Specialty Therapeutics
• FDA Approval Announcement: FDA Approves Two Oral Therapies to Treat Gonorrhea. Available at: FDA.gov
• Clinical Trial Details: Zoliflodacin in Uncomplicated Gonorrhoea (EAGLE-1). ClinicalTrials.gov Identifier: NCT03959527. Available at: ClinicalTrials.gov